China is revolutionizing breast cancer care with cutting-edge therapies that are rapidly gaining ground across its top cancer hospitals. Here are the most notable and recent advancements that demonstrate China's growing leadership in personalized cancer treatment.
1. Trastuzumab Deruxtecan (DS-8201) – A Game-Changer for HER2-Positive and HER2-Low BC
Widely adopted in major hospitals like Fudan University Cancer Center, this ADC has shown remarkable efficacy in HER2-positive and HER2-low metastatic breast cancer, especially in patients resistant to traditional anti-HER2 therapies.
2. Dalpiciclib – A Cost-Effective CDK4/6 Inhibitor Made in China
Dalpiciclib, developed domestically, is now a first-line treatment for HR+/HER2- advanced breast cancer. Offering comparable efficacy to Palbociclib, it is a more affordable option and is widely used across China.
3. PD-1 Immunotherapy – New Hope for Triple-Negative Breast Cancer (TNBC)
Chinese hospitals are actively applying Toripalimab and Camrelizumab in neoadjuvant settings or in combination with chemotherapy for TNBC patients—especially in Beijing and Shanghai.
4. AKT Inhibitors (Ipatasertib) – Targeting PIK3CA Mutations in TNBC
Through expanded access programs and clinical trials, China is treating PIK3CA-mutant TNBC with AKT inhibitors such as Ipatasertib, achieving promising survival outcomes.
5. CAR-T and TIL Therapy – Advanced Cell Therapies Under Research
Select hospitals like Wu Mengchao Cancer Center are pioneering trials for CAR-T therapies targeting Claudin 18.2 and MUC1, especially in patients with metastatic breast cancer who failed standard treatments.
6. Breakthrough CAR-T: BZD1901 for Mesothelin-Positive Tumors
BZD1901 is an innovative CAR-T therapy with self-secreting PD-1 nanobody, showing:
- 100% Disease Control Rate in mesothelioma
- High safety profile and durable responses
This therapy targets cancers expressing mesothelin, including breast, gastric, ovarian, lung, and pancreatic cancers, and is part of China’s "Bai Ze Plan" to bring CAR-T to 60% of cancer patients within 10 years.
